Table 2.
Clinical details of human breast tumors utilized in this study
| Breast tumor sample set: Origin | Set A: DBCG82 b/c | Set C: MDACC |
|---|---|---|
| Patient number | 128 | 95 |
| Tumor subtype | ||
| Hormone receptor (HR)-positive | 42 (LumA), 27 (LumB), 17 (normal-like) |
64 |
| HER2-positive | 18 (erbB2) | 10 |
| Triple (receptor)-negative | 24 (basal) | 21 |
| Stage | ||
| Unknown | 0 | 0 |
| Ductal carcinoma in situ (DCIS) | 0 | 3 |
| 1 | 1 | 17 |
| 2 | 63 | 46 |
| 3 | 64 | 22 |
| 4 | 0 | 7 |
| Grade | ||
| 1 | 19 | 6 |
| 2 | 52 | 38 |
| 3 | 30 | 49 |
| Unknown | 27 | 2 |
| Adjuvant treatment | ||
| Tamoxifen | 77 | 19 |
| Aromatase inhibitor | 0 | 38 |
| Cytotoxic chemotherapy | 51 (CMF) | 65 (anthracycline and/or taxane) |
| Trastuzumab | 0 | 1 |
In the Danish DBCG82 b and c breast cancer studies (Set A), premenopausal women with high-risk breast cancer were randomized to receive radiation therapy plus cyclophosphamide, methotrexate, and fluorouracil (CMF) or to CMF chemotherapy alone, and postmenopausal women with high-risk breast cancer were randomized to receive radiation therapy plus tamoxifen (30 mg daily for 1 year) or tamoxifen alone (PMID: 10335782)
CMF cyclophosphamide, methotrexate, and fluorouracil, Lum luminal, MDACC M. D. Anderson Cancer Center